How to compare longevity/anti-aging clinics worldwide? Regulations in Taiwan, Japan, and the US at a glance
When comparing longevity/anti-aging medicine across countries, the most critical difference lies in the regulatory stringency of cell and regenerative medicine. Taiwan has opened six types of autologous cell therapies at approved institutions since September 2018 under the Special Regulations on Cell Therapy, and passed the Regenerative Medicine Act and the Regenerative Medicine Preparations Act (the dual regenerative laws) in 2024. Japan, under the Act on Ensuring Safety of Regenerative Medicine (2014), adopts a three-tier risk-based review with faster conditional approvals and a higher number of private clinics offering such treatments. The US FDA strictly regulates human cell products as biologics, and most "anti-aging stem cell" therapies are not approved, with enforcement actions taken against non-compliant clinics. The following provides a neutral comparison of regulations and current status across these three regions, without ranking or constituting medical advice.
Comparison of Regulatory Stringency in Taiwan, Japan, and the US
When comparing longevity/anti-aging medicine across countries, the most critical difference lies in the regulatory stringency of cell and regenerative medicine:
- Taiwan: Opened six types of autologous cell therapies at approved institutions since 2018 under the Special Regulations, and passed the dual regenerative laws in 2024
- Japan: Under the 2014 Act on Ensuring Safety of Regenerative Medicine, adopts a three-tier risk-based review with faster conditional approvals, and more private clinics offer such treatments
- US: FDA strictly regulates human cell products as biologics; most 'anti-aging stem cell' therapies are unapproved and enforcement actions have been taken against non-compliant clinics
Why the phrase 'Taiwan enthusiastic, Japan hitting the brakes'
Media have used this phrase to describe the different paces, reflecting different trade-offs between 'open access' and 'evidence and safety oversight':
- After Taiwan's Special Regulations opened, applications and procedures grew rapidly
- Japan, despite earlier openness, saw authorities and academia become more cautious due to lack of clear efficacy evidence and safety concerns for some self-paid regenerative treatments
- Any treatment should be based on scientific evidence and qualified physician evaluation
What to consider when seeking treatment abroad
Cross-border medical care carries higher risks; it is recommended to confirm each item in advance:
- Whether the technology is legal and within approved scope in that country (varies by country)
- Qualifications of the institution and physician, level of scientific evidence for the treatment
- Costs and refund policies, language barriers, emergency medical care, and follow-up care after returning home
- The World Health Organization and regulatory authorities in multiple countries warn against 'stem cell tourism' and exaggerated claims.
FAQ
What are the differences in cell/regenerative medicine regulations among Taiwan, Japan, and the US?
Taiwan's 2018 Special Regulations on Cell Therapy opened six types of autologous cell therapies (e.g., immune cells, adipose-derived stem cells, bone marrow mesenchymal stem cells) to be performed only by Ministry of Health and Welfare-approved medical institutions within approved scopes; the dual regenerative laws took effect in 2024. Japan's 2014 Act on Ensuring Safety of Regenerative Medicine adopts a three-tier risk-based review with faster conditional approvals, and more private clinics offer such treatments. The US FDA strictly regulates cell products as biologics; most anti-aging stem cell therapies are unapproved, and enforcement actions have been taken against non-compliant clinics. The three regions differ significantly in "permissible scope" and "regulatory stringency" (sources: Taiwan MOHW, Japan MHLW, US FDA).
Why do some reports say 'Taiwan is enthusiastic while Japan is hitting the brakes'?
Media have used this phrase to describe the different paces: after Taiwan's Special Regulations opened, applications and procedures grew rapidly. Japan, despite earlier openness, saw authorities and academia become more cautious due to lack of clear efficacy evidence and safety concerns for some self-paid regenerative treatments. This reflects different trade-offs between 'open access' and 'evidence and safety oversight' across countries (sources: CommonWealth Magazine, The Reporter). This site does not judge superiority, and reminds that any treatment should be based on scientific evidence and qualified physician evaluation.
What should I consider when seeking anti-aging/cell therapy abroad?
Cross-border medical care requires attention to: ① whether the technology is legal and within approved scope in that country (varies by country) ② qualifications of the institution and physician ③ level of scientific evidence for the treatment (many anti-aging stem cell therapies are still investigational or unapproved) ④ costs and refund policies, language barriers, and emergency medical care ⑤ follow-up care after returning home. The WHO and many national authorities warn against 'stem cell tourism' and exaggerated claims; do not decide based solely on advertisements.
What is the current situation in Taiwan? Where can I check approved items?
In Taiwan, autologous cell therapies within the scope of the Special Regulations can be received at MOHW-approved medical institutions. Approved technologies and institutions can be found on the MOHW 'Cell Therapy Technology Information Zone' (celltherapy.mohw.gov.tw); the number of approved projects continues to grow (latest numbers as per the zone's announcements). Dermatology, plastic surgery, functional medicine, and other anti-aging clinics are also common. This site compiles publicly available information on related clinics nationwide as a neutral starting point for local understanding.
This page is a neutral compilation of information for reference only, not medical advice, and does not constitute any diagnostic commitment.